Cell Source, Inc. (CLCS)
Stock Price: $1.55 USD
0.00 (0.00%)
Updated Feb 24, 2021 9:30 AM EST - Market closed
| Market Cap | 57.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.72M |
| Shares Out | 31.85M |
| EPS (ttm) | -0.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $1.55 |
| Previous Close | $1.55 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 1.55 |
| Day's Range | 1.55 - 1.55 |
| Day's Volume | 0 |
| 52-Week Range | 0.4101 - 2.55 |
News
There are no news available yet.
About CLCS
Cell Source, a cell therapy company, focuses on developing and commercializing immunotherapy medicines in Israel. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, such as treatment of lymphoma, leukemia, and multiple myeloma; and facilitating the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant or... [Read more...]
| Industry Biotechnology | Founded 2011 |
| Stock Exchange OTCMKTS | Ticker Symbol CLCS |